Analytical and clinical validation of an LC-MS/MS method for urine leukotriene E4: A marker of systemic mastocytosis.

Autor: Lueke AJ; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, United States., Meeusen JW; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, United States. Electronic address: meeusen.jeffrey@mayo.edu., Donato LJ; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, United States., Gray AV; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, United States., Butterfield JH; Department of Medicine, Division of Allergic Diseases, Mayo Clinic, Rochester, MN, United States; Mayo Clinic Program for Mast Cell and Eosinophil Disorders, Mayo Clinic, Rochester, MN, United States., Saenger AK; Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, United States.
Jazyk: angličtina
Zdroj: Clinical biochemistry [Clin Biochem] 2016 Sep; Vol. 49 (13-14), pp. 979-82. Date of Electronic Publication: 2016 Feb 18.
DOI: 10.1016/j.clinbiochem.2016.02.007
Abstrakt: Objectives: Systemic mastocytosis (SM) is a disorder characterized by the excessive accumulation of clonally derived mast cells in various tissues. When triggered, mast cells release large amounts of histamine, prostaglandins and leukotrienes. Leukotriene E4 (LTE4) is the primary stable metabolite of total cysteinyl leukotrienes. We hypothesized that secretion of LTE4 would be increased in SM and could be used alone or in combination with current urinary biomarkers to optimize screening for SM.
Design and Methods: LTE4 was measured by liquid chromatography followed by tandem mass spectrometry (LC-MS/MS). Analytical assay validation was performed using residual urine specimens. LTE4 results were normalized to urine creatinine for clinical use. Reference interval was established using a healthy volunteer cohort. Clinical sensitivity and specificity for SM detection were determined by measuring urinary biomarkers (LTE4, N-methyl histamine [NMH] and 11β-prostaglandin F2α [BPG]) in a cohort of 409 patients referred to allergy specialists, 66 (16%) of which were diagnosed with SM.
Results: Urinary LTE4 measurement was accurate, precise and linear across a range of 31-3020pg/mL. The 95th percentile of the reference interval population was <104pg/mg creatinine. Median urine LTE4 concentrations were significantly higher among patients with SM (97pg/mg cr. vs. 50pg/mg cr.; p<0.01). Elevated urinary LTE4 was 48% sensitive and 84% specific for SM. Clinical sensitivity was 53% for BPG (>1000ng/mL) and 71% for NMH (>200ng/mL). Incorporating all three urinary metabolites improved the SM diagnostic sensitivity to 97%, with minimal change in specificity.
Conclusions: We have developed a sensitive and precise LC-MS/MS assay for quantitation of LTE4 in urine. Incorporating LTE4 into a panel including BPG and NMH provides a much-needed screening tool for a complicated disease with non-specific symptoms and invasive confirmatory testing.
(Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: